These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

327 related items for PubMed ID: 25283354

  • 1. Practical management of sunitinib toxicities in the treatment of pancreatic neuroendocrine tumors.
    Valle JW, Faivre S, Hubner RA, Grande E, Raymond E.
    Cancer Treat Rev; 2014 Dec; 40(10):1230-8. PubMed ID: 25283354
    [Abstract] [Full Text] [Related]

  • 2. Sunitinib and everolimus in pancreatic neuroendocrine tumors.
    Procopio G, Pusceddu S, Buzzoni R.
    Tumori; 2012 Dec; 98(3):394. PubMed ID: 22825518
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors.
    Raymond E, Dahan L, Raoul JL, Bang YJ, Borbath I, Lombard-Bohas C, Valle J, Metrakos P, Smith D, Vinik A, Chen JS, Hörsch D, Hammel P, Wiedenmann B, Van Cutsem E, Patyna S, Lu DR, Blanckmeister C, Chao R, Ruszniewski P.
    N Engl J Med; 2011 Feb 10; 364(6):501-13. PubMed ID: 21306237
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Activity of sunitinib in patients with advanced neuroendocrine tumors.
    Kulke MH, Lenz HJ, Meropol NJ, Posey J, Ryan DP, Picus J, Bergsland E, Stuart K, Tye L, Huang X, Li JZ, Baum CM, Fuchs CS.
    J Clin Oncol; 2008 Jul 10; 26(20):3403-10. PubMed ID: 18612155
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. FDA approval summary: sunitinib for the treatment of progressive well-differentiated locally advanced or metastatic pancreatic neuroendocrine tumors.
    Blumenthal GM, Cortazar P, Zhang JJ, Tang S, Sridhara R, Murgo A, Justice R, Pazdur R.
    Oncologist; 2012 Jul 10; 17(8):1108-13. PubMed ID: 22836448
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Efficacy and safety of everolimus and sunitinib in patients with gastroenteropancreatic neuroendocrine tumor.
    Yoo C, Cho H, Song MJ, Hong SM, Kim KP, Chang HM, Chae H, Kim TW, Hong YS, Ryu MH, Kang YK, Kim SC, Ryoo BY.
    Cancer Chemother Pharmacol; 2017 Jan 10; 79(1):139-146. PubMed ID: 27942928
    [Abstract] [Full Text] [Related]

  • 13. Severe resistant hypoglycemia in a patient with a pancreatic neuroendocrine tumor on sunitinib treatment.
    Fountas A, Tigas S, Giotaki Z, Petrakis D, Pentheroudakis G, Tsatsoulis A.
    Hormones (Athens); 2015 Jan 10; 14(3):438-41. PubMed ID: 25553766
    [Abstract] [Full Text] [Related]

  • 14. Clinical efficacy and safety of sunitinib after imatinib failure in Japanese patients with gastrointestinal stromal tumor.
    Matsumoto K, Sawaki A, Mizuno N, Hara K, Hijioka S, Niwa Y, Tajika M, Kawai H, Kondo S, Yamao K.
    Jpn J Clin Oncol; 2011 Jan 10; 41(1):57-62. PubMed ID: 20858619
    [Abstract] [Full Text] [Related]

  • 15. Pancreatic neuroendocrine tumors: signal pathways and targeted therapies.
    Peng L, Schwarz RE.
    Curr Mol Med; 2013 Mar 10; 13(3):333-9. PubMed ID: 23331005
    [Abstract] [Full Text] [Related]

  • 16. Response by Choi criteria to sunitinib plus octreotide LAR in a functional heavily pretreated advanced pancreatic neuroendocrine tumor.
    Grande E, José Díez J, Pachón V, Angeles Vaz M, Longo F, Guillén C, García de Paredes ML, Carrato A.
    Anticancer Drugs; 2011 Jun 10; 22(5):477-9. PubMed ID: 21346550
    [Abstract] [Full Text] [Related]

  • 17. Pharmacokinetics and pharmacodynamics of sunitinib for the treatment of advanced pancreatic neuroendocrine tumors.
    Bisht S, Feldmann G, Brossart P.
    Expert Opin Drug Metab Toxicol; 2013 Jun 10; 9(6):777-88. PubMed ID: 23590356
    [Abstract] [Full Text] [Related]

  • 18. Safety and efficacy of sunitinib in patients from Italy with metastatic renal cell carcinoma: final results from an expanded-access trial.
    Sternberg CN, Calabrò F, Bracarda S, Cartenì G, Lo Re G, Ruggeri EM, Basso U, Gasparini G, Ciuffreda L, Ferrari V, Bonetti A, Fea E, Gasparro D, Tassinari D, Labianca R, Masini C, Fly K, Zhang K, Hariharan S, Capaccetti B, Porta C.
    Oncology; 2015 Jun 10; 88(5):273-80. PubMed ID: 25592399
    [Abstract] [Full Text] [Related]

  • 19. Sunitinib: Ten Years of Successful Clinical Use and Study in Advanced Renal Cell Carcinoma.
    Motzer RJ, Escudier B, Gannon A, Figlin RA.
    Oncologist; 2017 Jan 10; 22(1):41-52. PubMed ID: 27807302
    [Abstract] [Full Text] [Related]

  • 20. A shining light in the darkness for the treatment of pancreatic neuroendocrine tumors.
    Capdevila J, Tabernero J.
    Cancer Discov; 2011 Aug 10; 1(3):213-21. PubMed ID: 22586573
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.